Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Background Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21 …

Background Mantle-cell lymphoma is generally incurable. Despite high rates of complete
response after initial immunochemotherapy followed by autologous stem-cell …

Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy and
represents 5%–7% of malignant lymphoma in Western Europe. The annual incidence of this …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

Purpose Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose
considerable variability of individual outcome is associated with clinical characteristics …

Background The proteasome inhibitor bortezomib was initially approved for the treatment of
relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for …